BATs in Patients With Breast Cancer and Leptomeningeal Metastases
Status:
Recruiting
Trial end date:
2025-08-30
Target enrollment:
Participant gender:
Summary
This study uses bi-specific antibody (HER2Bi) armed activated T-cells (HER2 BATs) to target
breast cancer cells that have metastasized to the membranes surrounding the brain and spinal
cord. This is known as leptomeningeal metastases. Two doses will be evaluated in order to
determine a safe dose.
Study treatment includes a test dose of HER2 BATs followed by 8 weekly infusions of HER2 BATs
at the assigned dose level. Before, during and after study treatment, participants will be
monitored objectively by brain MRIs and clinically through physical and neurological exams,
and blood and cerebrospinal fluid will be collected to evaluate immune responses.